JP5883222B2 - 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 - Google Patents

心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 Download PDF

Info

Publication number
JP5883222B2
JP5883222B2 JP2010528515A JP2010528515A JP5883222B2 JP 5883222 B2 JP5883222 B2 JP 5883222B2 JP 2010528515 A JP2010528515 A JP 2010528515A JP 2010528515 A JP2010528515 A JP 2010528515A JP 5883222 B2 JP5883222 B2 JP 5883222B2
Authority
JP
Japan
Prior art keywords
phenyl
treatment
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010528515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500550A (ja
JP2011500550A5 (enExample
Inventor
ジェンク フランソワ
ジェンク フランソワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5883222(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2011500550A publication Critical patent/JP2011500550A/ja
Publication of JP2011500550A5 publication Critical patent/JP2011500550A5/ja
Application granted granted Critical
Publication of JP5883222B2 publication Critical patent/JP5883222B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010528515A 2007-10-10 2008-10-09 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 Expired - Fee Related JP5883222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2007/054130 2007-10-10
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (3)

Publication Number Publication Date
JP2011500550A JP2011500550A (ja) 2011-01-06
JP2011500550A5 JP2011500550A5 (enExample) 2011-10-20
JP5883222B2 true JP5883222B2 (ja) 2016-03-09

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528515A Expired - Fee Related JP5883222B2 (ja) 2007-10-10 2008-10-09 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007337659A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
EP2638008B1 (en) 2010-11-10 2015-07-01 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
SI2776430T1 (sl) 2011-11-08 2016-06-30 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
CN105793257B (zh) 2013-12-03 2018-11-13 爱杜西亚药品有限公司 苯并咪唑环化合物的晶形及其用途
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
JP6659681B2 (ja) 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法
JP7179049B2 (ja) * 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234840T3 (es) 2000-03-14 2005-07-01 Actelion Pharmaceuticals Ltd. Derivados de 1,2,3,4- tetrahidroisoquinolina.
RU2345985C2 (ru) * 2003-03-26 2009-02-10 Актелион Фармасьютиклз Лтд. Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора
RU2378257C2 (ru) * 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
EA015256B1 (ru) * 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Also Published As

Publication number Publication date
CA2699504C (en) 2015-11-24
ZA201003251B (en) 2011-07-27
IL204838A0 (en) 2010-11-30
EA201000557A1 (ru) 2010-10-29
AU2008309194A1 (en) 2009-04-16
WO2009047723A3 (en) 2009-05-28
ES2444418T3 (es) 2014-02-25
PT2207550E (pt) 2014-02-07
AR068768A1 (es) 2009-12-02
UA99150C2 (ru) 2012-07-25
NZ585086A (en) 2012-03-30
CA2699504A1 (en) 2009-04-16
EA017443B1 (ru) 2012-12-28
CY1114799T1 (el) 2016-12-14
TWI428129B (zh) 2014-03-01
EP2207550B1 (en) 2013-12-11
MY153044A (en) 2014-12-31
MA31800B1 (fr) 2010-10-01
HK1145440A1 (en) 2011-04-21
US9532985B2 (en) 2017-01-03
PL2207550T3 (pl) 2014-05-30
KR101733247B1 (ko) 2017-05-08
AU2008309194B2 (en) 2013-10-03
DK2207550T3 (da) 2014-01-27
SI2207550T1 (sl) 2014-03-31
IL204838A (en) 2014-09-30
JP2011500550A (ja) 2011-01-06
HRP20140214T1 (hr) 2014-04-11
KR20100065203A (ko) 2010-06-15
WO2009047723A2 (en) 2009-04-16
TW200932231A (en) 2009-08-01
MX2010003711A (es) 2010-04-30
PE20091010A1 (es) 2009-08-08
US20100234420A1 (en) 2010-09-16
CN101820878B (zh) 2012-02-01
EP2207550A2 (en) 2010-07-21
CN101820878A (zh) 2010-09-01
BRPI0818617A2 (pt) 2015-04-07

Similar Documents

Publication Publication Date Title
JP2011500550A (ja) 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体
JP5582535B2 (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
JP5456687B2 (ja) ニコチン作動薬を含む組成物及びそれを用いる方法
ZA200307156B (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV.
UA123352C2 (uk) Застосування похідних піридазину для попередження або лікування атаксичного синдрому
EA019354B1 (ru) Применение димирацетама для лечения хронической боли
IL257314A (en) A selected amide of gamma-hydroxybutyric acid and its uses in the treatment of alcohol abuse
KR101187461B1 (ko) 각성을 향상시키는 방법
AU735980B2 (en) A method of treating liver disease and like indications with vasodilating agents
TW544311B (en) Therapeutic or preventive agent for intractable epilepsies
JP2005507411A (ja) 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
KR102040639B1 (ko) 히스타민-3 수용체 역효능제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
Sévoz-Couche et al. Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat
KR100350156B1 (ko) 혈관확장제로간질환및관련증상을치료하는방법 및 이에 사용되는 조성물
WO2025102989A1 (zh) 靶向O-GlcNAc糖苷水解酶抑制剂促进髓鞘再生
CA3018375C (en) Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
JP2023539391A (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
CN101242836A (zh) 改善觉醒状态的方法
BR112019002645B1 (pt) Combinação, uso da combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer, composição farmacêutica
HK1263278B (en) Triple combination product of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist
HK1263278A1 (en) Triple combination product of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160205

R150 Certificate of patent or registration of utility model

Ref document number: 5883222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees